Prognostic Performance of the Next-Generation Sequencing-Based Multigene Assay in Early Breast Cancer Patients Treated According to the 21-Gene Assay Results
OncoFREE showed strong concordance with ODX and effectively identified high-risk patients, particularly in younger individuals. It could be an affordable alternative to ODX for guiding treatment in hormone receptor-positive early breast cancer.
Authors
- Wonshik Han (ORCID: https://orcid.org/0000-0001-7310-0764)
- Eunhye Kang
- Hee Jin Lee
- S. Lee
- Jiwon Koh (ORCID: https://orcid.org/0000-0002-7687-6477)
- Han‐Byoel Lee (ORCID: https://orcid.org/0000-0003-0152-575X)
- Jeongeun Son
- H.W. Lee (ORCID: https://orcid.org/0009-0009-6316-7354)
- Jiyoung Park (ORCID: https://orcid.org/0000-0002-0399-7083)
- Jeeyeon Lee (ORCID: https://orcid.org/0000-0003-1826-1690)
- Bum Joon Kim (ORCID: https://orcid.org/0000-0002-3278-3252)
- B. K. Kang
- Jai Min Ryu
- Woosung Chung
- Jong-Ho Cheun
- Woong Ki Park
Institutions
- Ulsan College (KR)
- Seoul National University (KR)
- Seoul Metropolitan Government (KR)
- Kyungpook National University Hospital (KR)
- Asan Medical Center (KR)
- Samsung Medical Center (KR)
- Seoul National University Hospital (KR)
- University of Ulsan (KR)
- SNUH SMG-SNU Boramae Medical Center (KR)
- ToolGen (South Korea) (KR)
- Sungkyunkwan University (KR)
Publication Details
- Journal
- Cancer Research and Treatment
- Published
- 2024-12-23
- DOI
- https://doi.org/10.4143/crt.2024.1035
- Citations
- 2
- Primary Topic
- Cancer Genomics and Diagnostics
- Type
- article
- Field-Weighted Citation Impact
- 0.57
Funders
- National Research Foundation
- Seoul National University
- National Research Foundation of Korea
- Seoul National University Hospital